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T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of blood cancer resulting 
from malignant transformation of a T-cell precursor. Several driver oncogenes, including the 
TLX1 transcription factor, have been identified as early events that cooperate with other 
genetic aberrations in the leukemic transformation of progenitor T-cells. Long non-coding 
RNAs (lncRNAs) have recently emerged as key players in cancer. In a first step towards 
unraveling the role of lncRNAs in T-ALL, we established T-ALL subgroup-specific lncRNA 
expression patterns (Wallaert et al., 2017). We also established the TLX1 regulome through 
integration of TLX1 and H3K27ac ChIP-sequencing with transcriptome data of ALL-SIL 
leukemic cells upon TLX1 knockdown (Durinck et al., Leukemia, 2015) and showed a crucial 
role for TLX1 in regulation of super-enhancer sites and a key set of T-ALL tumor suppressor 
genes. Next, we performed further in-depth analysis of the TLX1 regulome through an 
integrative (epi)genomics approach combining polyA+ and total RNA sequencing of ALL-SIL 
with TLX1 knockdown and primary T-ALL patients (n=64, including 17 TLX-subtype patients) 
as well as ATAC- and ChIP-sequencing (TLX1, H3K27ac, H3K4me1, H3K4me3). We 
observed a strong association of TLX1 to enhancer lncRNAs (eRNAs) sites. Moreover, we also 
identified a set of previously unannotated lncRNAs regulated by TLX1. Finally, using the 
ChromiumTM single cell device we performed single cell transcriptome analysis on ALL-SIL 
cells to better understand TLX1 knock-down effects on target genes. In conclusion, our works 
reveals for the first time a comprehensive view on the enhancer landscape and lncRNAome 
regulated by TLX1 in T-ALL and provides novel therapeutic avenues for targeted treatment of 
TLX positive T-ALL.   
 
